Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing of additional artery opening after heart attack could save lives

NCT ID NCT04626882

Disease control Sponsor: Chonnam National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial looks at the best time to reopen other blocked arteries in people who have just had a major heart attack (STEMI) and have multiple narrowed heart arteries. Participants are randomly assigned to have all blockages fixed right away or in a separate procedure later. A special guidewire (FFR) helps decide which blockages need treatment. The goal is to see which timing leads to fewer deaths, repeat heart attacks, or unplanned procedures over one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fractional flow reserve (FFR)-guided complete revascularization (procedure)
What this could lead to
If it works, this could establish the best timing for treating additional blocked arteries after a heart attack, potentially reducing deaths, repeat heart attacks, and the need for further procedures.
What could go wrong
This is a single-country trial with 994 participants, so results may not apply to all populations. The timing strategy may not improve outcomes and could carry risks like kidney damage from contrast dye.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

994 people

The number who actually took part.

Started

Dec 2019

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 19 years old * ST-segment elevation myocardial infarction * ST-segment elevation in at least 2 contiguous leads or, * New onset left bundle branch block * Primary PCI within 12 hours after symptom development * Multivessel disease: Non-IRA with at least 2.5 mm diameter and 50% diameter stenosis by visual estimation * Patient's or protector's agreement about study design and the risk of PCI Exclusion Criteria: * Cardiogenic shock at initial presentation or after treatment of IRA * Unprotected left main coronary artery disease with at least 50% diameter stenosis by visual estimation * TIMI (Thrombolysis in Myocardial Infarction) flow at non-IRA ≤ 2 * Severe procedural complications (e.g. persistent no-reflow phenomenon, coronary artery perforation) which restricts study enrollment by operators' decision * Non-IRA lesion not suitable for PCI treatment by operators' decision * Chronic total occlusion at non-IRA * History of anaphylaxis to contrast agent * Pregnancy and lactation * Life expectancy \< 1-year * Severe valvular disease * History of CABG (coronary artery bypass graft), or planned CABG * Fibrinolysis before admission * Severe asthma * Patient's refusal to participate in study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multi-vessel coronary artery stenosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction coronary artery disorder coronary stenosis myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multi-vessel coronary artery stenosis Myocardial infarction, acute

Contacts and locations

Locations

  • Chonbuk National University Hospital

    Jeonju, South Korea

  • Chonnam National University Hospital

    Gwangju, South Korea

  • GangNeung Asan Hospital

    Gangneung, South Korea

  • Gyeongsang National University Changwon Hospital

    Changwon, South Korea

  • Gyeongsang National University Hospital

    Jinju, South Korea

  • Koera University Guro Hospital

    Seoul, South Korea

  • Kyung Hee University Hospital

    Seoul, South Korea

  • Presbyterian Medical Center

    Jeonju, South Korea

  • St. Carollo General Hospital

    Suncheon, South Korea

  • The Catholic University of Korea, Bucheon St. Mary's Hospital

    Bucheon-si, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

  • The Catholic University of Korea, Uijeongbu St. Mary's Hospital

    Uijeongbu-si, South Korea

  • Yeongnam University Medical Center

    Daegu, South Korea

  • Yonsei University, Wonju Severance Christian Hospital

    Wŏnju, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.